Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert A Lefkowitz

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
European Urology|May 23, 2024
Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 TrialKelly N Fitzgerald, Chung-Han Lee, Martin H Voss, et al.
Melanoma Research|October 30, 2016
Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanomaAlexander N Shoushtari, Mark J Bluth, Debra A Goldman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2022
Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic CorrelatesChung-Han Lee, Martin H Voss, Maria Isabel Carlo, et al.
Cancer Immunology Research|January 18, 2018
Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 BlockadeCharlotte E Ariyan, Mary Sue Brady, Robert H Siegelbaum, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2022
A Phase Ib/II Randomized Study of RO4929097, a Gamma-Secretase or Notch Inhibitor with or without Vismodegib, a Hedgehog Inhibitor, in Advanced SarcomaMrinal M Gounder, Evan Rosenbaum, Nian Wu, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 22, 2014
⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancerNeeta Pandit-Taskar, Joseph A O'Donoghue, Volkan Beylergil, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2024
Histology-Specific Clinical Trial of Lenvatinib and Pembrolizumab in Patients with SarcomaSujana Movva, Kenneth Seier, Viswatej Avutu, et al.
Journal for Immunotherapy of Cancer|May 4, 2026
Phase 2 study of palbociclib plus retifanlimab in patients with advanced dedifferentiated liposarcomaEvan Rosenbaum, Kenneth Seier, Rodrigo Gularte-Mérida, et al.
The New England Journal of Medicine|December 22, 2018
Sorafenib for Advanced and Refractory Desmoid TumorsMrinal M Gounder, Michelle R Mahoney, Brian A Van Tine, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 16, 2015
A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate CancerNeeta Pandit-Taskar, Joseph A O'Donoghue, Jeremy C Durack, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
European Urology|May 23, 2024
Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 TrialKelly N Fitzgerald, Chung-Han Lee, Martin H Voss, et al.
Melanoma Research|October 30, 2016
Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanomaAlexander N Shoushtari, Mark J Bluth, Debra A Goldman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2022
Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic CorrelatesChung-Han Lee, Martin H Voss, Maria Isabel Carlo, et al.
Cancer Immunology Research|January 18, 2018
Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 BlockadeCharlotte E Ariyan, Mary Sue Brady, Robert H Siegelbaum, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2022
A Phase Ib/II Randomized Study of RO4929097, a Gamma-Secretase or Notch Inhibitor with or without Vismodegib, a Hedgehog Inhibitor, in Advanced SarcomaMrinal M Gounder, Evan Rosenbaum, Nian Wu, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 22, 2014
⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancerNeeta Pandit-Taskar, Joseph A O'Donoghue, Volkan Beylergil, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2024
Histology-Specific Clinical Trial of Lenvatinib and Pembrolizumab in Patients with SarcomaSujana Movva, Kenneth Seier, Viswatej Avutu, et al.
Journal for Immunotherapy of Cancer|May 4, 2026
Phase 2 study of palbociclib plus retifanlimab in patients with advanced dedifferentiated liposarcomaEvan Rosenbaum, Kenneth Seier, Rodrigo Gularte-Mérida, et al.
The New England Journal of Medicine|December 22, 2018
Sorafenib for Advanced and Refractory Desmoid TumorsMrinal M Gounder, Michelle R Mahoney, Brian A Van Tine, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 16, 2015
A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate CancerNeeta Pandit-Taskar, Joseph A O'Donoghue, Jeremy C Durack, et al.
Pageof 6